Previous 10 | Next 10 |
Puhui Wealth Investment (NASDAQ:PHCF) +55%. Red Cat Holdings RCAT +50% after subsidiary receives five-year contract with NASA Paltalk (NASDAQ:PALT) +36%. Vinco Ventures (NASDAQ:BBIG) +16%. VIZIO Holding (NYSE:VZIO) +10%. U.S. Energy (NASDAQ:USEG) +8%. Syndax Pharmaceuticals (NASDAQ:...
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with po...
Syndax Appoints Martin H. Huber, M.D., to its Board of Directors PR Newswire WALTHAM, Mass. , Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing ...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2021 Earnings Conference Call August 09, 2021, 16:30 ET Company Participants Melissa Forst - Argot Partners Briggs Morrison - CEO & Director Daphne Karydas - CFO Michael Meyers - Chief Medical Officer & SVP Conference Call Participants Philip Nad...
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 p...
Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 PR Newswire WALTHAM, Mass. , Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical sta...
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias PR Newswire WALTHAM, Mass. , June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopha...
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire WALTHAM, Mass. , June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutic...
Canopy set for growth on Canadian economy re-openingWhile not expecting a significant Q4 2021 beat for Canopy Growth (CGC) on June 1, MKM expects a turnaround as the Canadian economy starts to re-open.As a result, the firm is upgrading shares from neutral to buy with a C$55 price target.That ...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...